Enova International Amends $535M HWCR 2023 Securitization Facility

What Happened
Enova International, Inc. announced on September 17, 2026 that its wholly‑owned indirect subsidiary HWC Receivables 2023, LLC (HWCR 2023) entered into an Omnibus Amendment to amend its existing HWCR 2023 revolving receivables securitization facility. The amendment (Amendment No. 3 to the Credit Agreement and Amendment No. 1 to the Backup Servicing Agreement) updates terms of the facility and was executed with the facility’s lenders and agents, including Headway Capital, Vervent Inc., Deutsche Bank Trust Company Americas and Atlas Securitized Products Administration, L.P. The filing also reports the creation of a direct financial obligation by the subsidiary in connection with the amended securitization facility.

Key Details

• Total facility commitment: $535,000,000 (Class A $400M; Class B $135M).
• Borrowing rates (adjusted SOFR basis): Class A = SOFR + 2.75%; Class B = SOFR + 8.50%; blended/total = SOFR + 4.20%.
• Borrowing base advance rates: Class A = 65.5%; Class B = 87.5%; total = 87.5%.
• Key dates: Revolving period ends March 2028; maturity date March 2029.
• Parties: HWCR 2023 (borrower), Headway Capital (originator), Vervent (backup servicer), Deutsche Bank (paying agent/custodian), Atlas (administrative & collateral agent).
• The Omnibus Amendment will be filed as an exhibit to Enova’s Form 10‑Q for the quarter ending Sept. 30, 2026 (description in the 8‑K is qualified by that agreement).

Why It Matters
This amendment governs a material source of funding for receivables held by Enova’s subsidiary and establishes a direct financial obligation tied to that securitization facility. The $535M committed capacity, the SOFR‑based borrowing spreads, and the March 2029 maturity affect Enova’s funding availability, interest expense profile, and near‑term refinancing timeline. Investors should review the forthcoming credit agreement exhibit in Enova’s 10‑Q for full terms and any potential effects on consolidated liquidity or leverage.